Compare WAL & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAL | PCVX |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | 3524 | 507 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.8B |
| IPO Year | N/A | 2020 |
| Metric | WAL | PCVX |
|---|---|---|
| Price | $74.47 | $52.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $91.69 | $88.25 |
| AVG Volume (30 Days) | 981.1K | ★ 1.3M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.49 | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.82 | $29.10 |
| 52 Week High | $97.23 | $65.00 |
| Indicator | WAL | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 36.95 |
| Support Level | $74.13 | $52.04 |
| Resistance Level | $81.21 | $56.04 |
| Average True Range (ATR) | 2.40 | 2.51 |
| MACD | -0.90 | -0.51 |
| Stochastic Oscillator | 5.11 | 33.53 |
Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.